Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DOACs surpass warfarin in low-weight AFib patients

Key clinical point: Direct-acting oral anticoagulants appeared to be safer and more effective than warfarin in low-weight patients with atrial fibrillation.

Major finding: In low-weight patients, the composite adverse-event endpoint occurred in 34% fewer patients on a DOAC compared with warfarin.

Study details: Analysis of outcomes of 21,679 low-weight patients with AFib treated with an oral anticoagulant in the Korean National Health Insurance database.

Disclosures: Dr. Lee had no disclosures.

Citation:

Lee SR et al. HRS 2019, Abstract S-AB30-05.